论文部分内容阅读
肠道病毒71型(enterovirus 71,EV71)是引起手足口病的主要病原体,研发疫苗是防控该病疫情的有效措施。目前全球已有5家企业或机构研发的单一基因型EV71全病毒灭活疫苗进入临床试验阶段。然而由于不同地区EV71流行株基因型不同,了解单一EV71疫苗株制备的疫苗对其他流行株的交叉保护能力,对疫苗的应用具有重要意义。本文对近年来EV71疫苗交叉保护能力的研究进展作一综述。
Enterovirus 71 (EV71) is the major causative agent of hand-foot-mouth disease. To develop a vaccine is an effective measure to prevent and control this epidemic. At present, five single-genotype EV71 whole-virus inactivated vaccines developed by 5 enterprises or institutions worldwide have entered the clinical trial phase. However, due to the different genotypes of EV71 strains in different regions, it is of great significance to understand the cross-protection ability of vaccines prepared from a single EV71 vaccine strain against other popular strains. This review summarizes the research progress of cross protection of EV71 vaccine in recent years.